Patient-Friendly Explanation
Survodutide is an investigational injection that mimics two natural hormones — GLP-1 and glucagon — to suppress appetite and boost calorie burning. Early clinical trials show significant weight loss, and it is also being studied for fatty liver disease.
Clinical Definition
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist with balanced activity at both receptors. Phase 2 data demonstrated up to 18.7% body weight reduction at 46 weeks. Concurrent GCGR agonism promotes hepatic lipid oxidation and may provide additional benefit in metabolic dysfunction-associated steatotic liver disease (MASLD).
Why It Matters
Survodutide’s dual liver and weight benefits make it particularly relevant for patients with concurrent fatty liver disease. The NuLifeCare Singapore team monitors these developments to guide future treatment pathways.